Status:
UNKNOWN
The Effects of Ankaferd Blood Stopper
Lead Sponsor:
Uludag University
Conditions:
Colon Cancer
Oral Mucositis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of oral care is to reduce the effect of oral pathological microbial flora and to prevent infection, pain, and bleeding associated with cancer treatment. New agents are introduced each day ...
Detailed Description
In patients with colorectal cancer, it is important to perform symptom management dynamically as well as specific treatments for cancer. It is extremely important for healthcare professionals to know ...
Eligibility Criteria
Inclusion
- between the ages of 18-75
- At least primary school graduate
- No communication problems
- No mouth sores/mucositis (Mucositis stage=0)
- Having been diagnosed with colorectal cancer
- To receive Folfox (5-Fluorouracil, oxalplatin, folinic acid) combination therapy as first-line therapy Not having received chemotherapy or radiotherapy with any other diagnosis before
- Agreeing to participate in the study
- ECOG performance status 0-2
Exclusion
- Don't be a denture
- Having an oral herpes simplex lesion
- Smoking
- Using Glutemine Research
- Receiving G-CSF support
- Having a physical disability that prevents them from using the right brushing technique
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 2 2023
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT05438771
Start Date
June 1 2021
End Date
June 2 2023
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bursa Uludag University
Bursa, Turkey (Türkiye), 16100